BioNTech (Zhuhai) Pharmaceuticals R&D

Pharmaceutical R&D subsidiary

Appears in 1 story · Last updated Nov 5, 2026

Stories

Bambusa Therapeutics files for IPO to fund eczema and inflammation drug trials

Money Moves

Sold BBT001 and BBT002 assets to Bambusa; collaboration partner

Bambusa Therapeutics priced an upsized Nasdaq IPO on Oct. 29, raising $168.9 million. It sold 10.56 million shares at $16 each, up from 9.38 million, and began trading under BBTX on Oct. 30.

Updated 6 days ago